Latest Blogs

Guest Commentary
Nov 28, 2023
Women Mentoring Women: A Thank You Note to My Two Heroes
Dr. Tara Rajendran honors two women who, through their kindness and thoughtful attention, shaped her professional path from an early age.
Linda R. Duska, MD, MPH
Nov 20, 2023
The Potential of AI in Clinical Research
"We all need to stay informed and engaged on the topic of AI in order to be the best advocates for ourselves, our profession, and our patients."
International Perspectives
Nov 03, 2023
Cancer, Conflict, and Catastrophe: A Cry for Help From Sudan, a Country at War
Millions of people have been affected by the war in Sudan, and the outlook for patients with cancer is particularly dire. Dr. Nabeeha Karadawi, Dr. Salma Awad Elkareem Ali Mohamed, and Nagham Ali outline the current situation and call for immediate international aid.
Abdul-Rahman Jazieh, MD, MPH
Oct 24, 2023
Should Oncologists Continue to Be Ambivalent About Dietary Supplement Use by Their Patients?
If we believe that dietary supplements are active compounds—and many are—then we should deal with them as medications and advise our patients accordingly.
Subscribe to this column

Clifford A. Hudis, MD, FASCO, FACP

Clifford A. Hudis, MD, FACP, FASCO, is the CEO of ASCO, executive vice chair of Conquer Cancer, the ASCO Foundation, and chair of CancerLinQ. Prior to these roles, he served as chief of the Breast Medicine Service and an attending physician at Memorial Sloan Kettering Cancer Center and as a professor in the Department of Medicine at Weill Cornell Medical College. He is a past president of ASCO. His research interests include all areas of care related to breast cancer, with a focus on the development of novel systemic therapies and prevention interventions related to obesity and inflammation. Follow Dr. Hudis on Twitter @CliffordHudis.

Disclosure.

Jun 04, 2020
Warm Wishes to Rich: ASCO Chief Medical Officer Dr. Richard L. Schilsky to Retire in February 2021
A spirit of clinically relevant discovery and accessible, understandable knowledge dissemination is the profound legacy, responsibility, and obligation that Rich will leave at ASCO, and we will honor him by continuing this work at the level of rigor and quality he established.
May 26, 2020
Drug Repository Programs: A Conversation With Dr. Ray Page
Dr. Ray Page and I discuss the important role that drug repository programs can play in helping our patients afford their treatment while reducing the financial toll on the cancer care delivery system.
May 20, 2020
New ASCO Registry Helps Cancer Community Learn About COVID-19’s Impact on Cancer Care
We have an urgent need to learn more about how COVID-19 is directly and indirectly affecting the people with cancer whom we serve.
Apr 20, 2020
CAR T-Cell Therapy: A Conversation With Dr. Jason Westin
Dr. Jason Westin explains the science behind the transformative CAR T-cell therapy, and the financial concern it presents to our health care system and our patients.
Apr 07, 2020
The Power of mCODE: A Conversation With Dr. Robert Miller
Dr. Robert Miller and I discuss electronic medical records, interoperability, and ASCO's role in developing a set of standardized data elements for oncology.
Mar 10, 2020
Cancer Advance of the Year: A Conversation With Dr. Richard L. Schilsky
ASCO's chief medical officer Dr. Richard L. Schilsky and I discuss the refinement of cancer surgery, the critical importance of federally funded research, and ASCO's research priorities for the oncology community.

Pages